Evaluating HPV Testing After Chemoradiotherapy for Cervical Cancer A Study on Monitoring Disease Recurrence Using Cervical Swabs and Blood Samples

What this Trial Is About

Researchers are evaluating the use of HPV testing to monitor patients who have undergone chemoradiotherapy CRT for cervical cancer. This observational trial focuses on women with cervical cancer stages IB to IVA who received primary radiotherapy aimed at curing the disease. The study seeks to understand how well HPV-based molecular tests can detect cancer recurrence compared to current methods like clinical exams and imaging. The study will collect samples before treatment and during follow-up visits at 3, 12, and 24 months after CRT completion. HPV detection will be done using two methods PCR testing of HPV DNA from cervical swabs and analysis of circulating HPV DNA fragments in blood. These approaches aim to track HPV clearance and recurrence sensitivity over a two-year period. Participants will undergo sample collection and monitoring visits during the two years following treatment. Researchers will assess how accurately HPV DNA testing detects cancer recurrence and compare the effectiveness of cervical swabs versus blood tests. The study will also look at HPV types present before and after treatment and evaluate treatment outcomes for patients with detected recurrence.

HPV After chemoRadioTherapy